Oxidative stress and expression of insulin signaling proteins in the brain of diabetic rats: Role of Nigella sativa oil and antidiabetic drugs

PloS One
Mahmoud BalbaaSofia Khalil

Abstract

Insulin resistance of the brain is a specific form of type2-diabetes mellitus (T2DM) and the active insulin-signaling pathway plays a neuroprotective role against damaging conditions and Alzheimer's progression. The present study identifies the mediated emerging effects of the Nigella sativa oil (NSO) on the memory enhancing process, its anti-oxidative, acetylcholinestrase (AChE) inhibition, anti-brain insulin resistance and anti-amyloidogenic activities. In addition, the possible role of some anti-diabetic drugs in the neuro-protection processes and their effect in combination with NSO and/or the insulin receptor inhibitor IOMe-AG538 were investigated. T2DM-induced rats were orally and daily administrated 2.0 ml NSO, 100 mg metformin (MT), 0.8 mg glimepiride (GI) and different combinations (100 mg MT & 2.0 ml NSO, 0.8 mg GI & 2.0 ml NSO and 2.0 ml NSO & intraperitoneal injection of 1/100 LD50 of IOMe-AG538) per kg body weight for 21 days. A significant increase in the brain lipid peroxidation and decrease in the antioxidant status with peripheral and central production of pro-inflammatory mediators were observed in diabetes-induced rats. The brain AChE was activated and associated with diminished brain glucose level and cholin...Continue Reading

References

Jan 15, 2002·The Journal of Clinical Endocrinology and Metabolism·Yolanta T KruszynskaJerrold M Olefsky
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Jul 1, 1961·Biochemical Pharmacology·G L ELLMANR M FEATHER-STONE
Sep 23, 2003·Diabetes & Metabolism·P Beisswenger, D Ruggiero-Lopez
Dec 12, 2003·Phytotherapy Research : PTR·Ulrich KalusHolger Kiesewetter
Apr 23, 2004·Phytotherapy Research : PTR·Valiollah HajhashemiHadi Jafarabadi
Jun 28, 2005·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·K SrinivasanP Ramarao
Oct 8, 2005·Journal of Pharmacological Sciences·Akihiko WadaHideyuki Kobayashi
Jan 13, 2006·International Review of Psychiatry·Paul B Rosenberg
Feb 16, 2006·Proceedings of the National Academy of Sciences of the United States of America·Tianzheng YuYisang Yoon
Jul 11, 2006·European Journal of Pharmacology·Abdulhakeem A Al-MajedMahmoud N Nagi
Apr 25, 2008·Proceedings of the National Academy of Sciences of the United States of America·Sébastien S HébertBart De Strooper
Aug 30, 2008·American Journal of Physiology. Endocrinology and Metabolism·Sigalit Boura-Halfon, Yehiel Zick
Sep 5, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Masaru YamamotoTsuneya Ikezu
Feb 25, 2009·Proceedings of the National Academy of Sciences of the United States of America·Yaomin ChenFrancesca-Fang Liao
Jan 29, 2010·The New England Journal of Medicine·Henry W Querfurth, Frank M LaFerla
Mar 26, 2010·Methods in Molecular Biology·Kendall Mitchell, Michael J Iadarola
Apr 24, 2010·Journal of Alzheimer's Disease : JAD·Peter T Nelson, Wang-Xia Wang
Jun 22, 2010·Journal of Cellular Biochemistry·Justin L MottMartin E Fernandez-Zapico
Nov 3, 2010·Nutrition·Stephen CunnaneStanley I Rapoport
Nov 26, 2010·Proceedings of the National Academy of Sciences of the United States of America·Eva KicksteinSusann Schweiger
Mar 26, 2011·Journal of Cellular and Molecular Medicine·Domenico BoscoArturo Pujia
May 14, 2011·Brain Research·Yuanyuan ZongChuan Qin
May 21, 2011·The Journal of Pathology·Ying LiuCheng-Xin Gong
May 11, 2012·Neuroepidemiology·Kai-Chen WangChung-Yi Li
Jun 20, 2012·Nature Reviews. Neurology·Suzanne Craft
Oct 2, 2012·Journal of Neuroimmunology·Shivika RaiRakesh Shukla
Oct 16, 2012·Progress in Neurobiology·Rory JohnsonNoel J Buckley
Mar 30, 2013·Biochemical and Biophysical Research Communications·A H AlhebshiI Suzuki
Sep 26, 2013·CNS & Neurological Disorders Drug Targets·Gjumrakch AlievMarcella Reale

❮ Previous
Next ❯

Citations

Apr 19, 2020·Clinical and Experimental Pharmacology & Physiology·Sathiya SekarChangiz Taghibiglou
Dec 14, 2018·Neurochemical Research·Isabel H Salas, Bart De Strooper
Mar 28, 2020·Oxidative Medicine and Cellular Longevity·Habib YaribeygiAmirhossein Sahebkar
May 19, 2020·CNS & Neurological Disorders Drug Targets·Subrat Kumar BhattamisraHira Choudhury
Dec 15, 2020·Phytotherapy Research : PTR·Masoumeh FadisheiHossein Hosseinzadeh
Oct 27, 2020·Oxidative Medicine and Cellular Longevity·Małgorzata Kiełczykowska, Irena Musik
Mar 16, 2021·Journal of Food Biochemistry·Nada F Abo El-MagdMamdouh M El-Shishtawy
Jul 11, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Nahid AlimoradiReihaneh Fatehi

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA
PCR
MDA

Software Mentioned

SPSS
UVIBAND Image quantification

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: Microglia

Microglia are a type of glial cell found throughout the brain and spinal cord. Microglia have been found to be associated with Alzheimer's disease development and progression. Here are the latest discoveries pertaining to Alzheimer's disease and microglia.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Alzheimer's Disease: Early Markers

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive and behavioral decline. Targeting markers in the earliest stages of the disease may mitigate the progression of AD. This feed focuses on early diagnosis and markers, as well as environmental, pharmacological, and drug-response biomarkers associated with this disease.